Boehringer Ingelheim, [6713 - 6799] Kaiser Dr, Fremont, CA 94555, US

Napo Pharmaceuticals, Inc. is a San Francisco-based company dedicated to developing and commercializing prescription medicines that provide essential supportive care for individuals undergoing treatment for diseases like cancer. Their mission is to improve the comfort, quality of life, and dignity of patients experiencing treatment-related gastrointestinal distress, particularly overactive bowel symptoms such as chronic diarrhea, urgency, and incontinence. Napo Pharmaceuticals is currently focused on their Phase 3 pivotal OnTarget trial of Mytesi crofelemer, a preventative treatment for chemotherapy-induced overactive bowel, with comprehensive results expected in Q1 2024. They also support investigator-initiated studies exploring the potential of crofelemer for rare disease indications like short bowel syndrome and microvillus inclusion disease. Napo Pharmaceuticals takes pride in their responsible harvesting practices, sourcing their medicines from plants in rainforest regions. Their prescription medicines work through a novel mechanism of action, inhibitory modulation of two secretory chloride ion channels in the gastrointestinal tract. The company is committed to uncovering medical solutions to serve those in need, advancing their understanding through high-quality research conducted by external investigators. Environmental sustainability and social responsibility are paramount to Napo Pharmaceuticals, as they prioritize the responsible harvesting of their products and share benefits with the local communities that contribute to their mission.Generated from the website